Pear’s Implosion: The Billion Dollar DTx Reimbursement Failure

The recent implosion of Pear Therapeutics, once a darling of the digital therapeutics (DTx) space, serves as a stark, cautionary tale for investors and health plan executives navigating the complex intersection of AI, healthcare innovation, and value-based care. Despite achieving FDA clearance for its prescription digital therapeutics, Pear’s journey from a $1.3 billion valuation to bankruptcy in less than two years underscores a fundamental disconnect between regulatory approval and sustainable reimbursement in a value-driven ecosystem. Pear Therapeutics filed for Chapter 11 bankruptcy on April 7, 2023, with the bankruptcy case concluding with a final decree entered on May 23, 2024. This failure isn’t an isolated incident but rather a systemic risk, highlighting critical gaps in the commercialization pathway for even clinically validated digital health solutions.

The Promise and Peril of Digital Therapeutics

Pear Therapeutics was a pioneer, securing the first FDA De Novo classification for a prescription digital therapeutic, reSET, for substance use disorder, followed by reSET-O for opioid use disorder and Somryst for chronic insomnia. These were significant regulatory milestones, positioning Pear as a leader in a nascent field. Other companies like Omada Health, Big Health, Akili Interactive, and Click Therapeutics also pursued and achieved various levels of clinical validation and regulatory clearances for their respective DTx offerings. The underlying premise was compelling: software-based interventions could deliver evidence-based therapies, improve patient outcomes, and reduce healthcare costs. This vision resonated with investors, attracting substantial capital to the sector. However, as the Pear Therapeutics saga painfully illustrates, an FDA-cleared product does not automatically translate into a viable value-based care pathway. The relationship “Pear FDA-cleared but no VBC pathway” encapsulates the core challenge.

What Went Wrong: A Reimbursement Rubicon

Pear’s downfall wasn’t due to a lack of innovation or clinical efficacy, but rather an inability to establish a scalable reimbursement model. While FDA clearance validated the safety and effectiveness of their SaMD products, it did not guarantee payment from payers. Historically, unlike a pharmaceutical drug with established CPT codes and clear dispensing pathways, DTx solutions often lacked a defined reimbursement infrastructure. The traditional fee-for-service model, designed for in-person services and physical products, struggled to accommodate prescription digital therapeutics, though recent developments have begun to address this gap. This created a chasm between clinical utility and financial viability. The challenge was compounded by the varying requirements of health plans. While some payers might have engaged in pilot programs or one-off agreements, a broad, consistent reimbursement framework remained elusive. While historically the lack of standardized CMS Reimbursement Rules for DTx meant that each company, including Pear, Omada Health, Big Health, Akili Interactive, and Click Therapeutics, had to negotiate individual contracts, a resource-intensive and often slow process, CMS has since introduced specific pathways. In November 2024, CMS approved three new reimbursement codes (G0522, G0553, G0554) for Digital Mental Health Treatment (DMHT) interventions, which became operational in 2025 and were expanded in November 2025 to include digital therapeutics for ADHD, effective in 2026. Furthermore, while the absence of clear, widely adopted Category I CPT codes specifically for DTx historically made it difficult for providers to bill for these services, disincentivizing adoption, the American Medical Association has introduced new CPT codes for remote therapeutic monitoring, and the DMHT codes provide a billing mechanism for certain digital mental health treatments. Additionally, the “Access to Prescription Digital Therapeutics Act” (S.1702) was introduced in 2022 to create a new benefit category for PDTs in Medicare Part B, aiming to streamline the reimbursement process. Private payers are also beginning to adapt, with Cigna Healthcare announcing in September 2025 that it would start covering FDA-approved digital therapeutics. The SEC filings of Pear Therapeutics, particularly leading up to its bankruptcy, revealed the immense commercialization hurdles despite regulatory successes.

Root Causes: Misaligned Incentives and Data Deficiencies

The root causes of Pear’s reimbursement failure are multifaceted, stemming from misaligned incentives within the healthcare ecosystem and, crucially, insufficient outcomes-data requirements to satisfy value-based care models. The FDA De Novo pathway, while critical for novel devices, focuses primarily on safety and efficacy. It does not inherently assess health economic outcomes or cost-effectiveness, which are paramount for value-based contracts. Many DTx companies, including Pear, initially struggled to provide the robust, peer-reviewed outcomes data that payers demand for value-based arrangements. While clinical trials often demonstrate efficacy, they don’t always translate directly into the “real-world evidence” (RWE) required to prove AI healthcare cost reduction or AI health financial performance. Payers, particularly those operating under value-based care models, require compelling evidence of tangible savings and improved patient outcomes over time, not just clinical effectiveness in controlled settings. Without this data, justifying the price point of a DTx solution becomes exceptionally difficult. The Centers for Medicare & Medicaid Services (CMS) and its innovation center, CMMI, have been exploring various payment models, and while a fully comprehensive and scalable pathway for all DTx is still evolving, significant progress has been made. The introduction of DMHT codes and the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model, which began its first performance period in July 2026, represent concrete steps towards establishing clearer reimbursement pathways. Rock Health, in its analyses of digital health funding, consistently points to reimbursement as a persistent challenge, even for well-funded companies. The “DTx reimbursement failure = systemic risk” relationship highlights that this is not an isolated company problem, but an industry-wide hurdle that impacts the entire digital health investment landscape. CW6-DP-12; CW6-DP-15

Expert Framing: A Call for Outcomes and Integration

Prominent voices in healthcare have long emphasized the need for a more outcomes-driven approach. Dr. Eric Topol, a leading cardiologist and digital medicine expert, has consistently advocated for digital health tools that demonstrate clear, measurable benefits. His perspective aligns with the core tenet of value-based care: solutions must prove their worth, not just their technological prowess. Similarly, venture capitalist Vinod Khosla, known for his bold predictions and investments in disruptive technologies, has often stressed the importance of demonstrable value and scalability for health tech ventures. For Khosla, innovation must translate into tangible impact and economic viability. The challenge for DTx, as highlighted by Pear’s experience, is that the “value” was not sufficiently articulated or proven to the entities holding the purse strings, the payers. While the clinical benefits might have been clear to clinicians and patients, the financial benefits, particularly in terms of AI healthcare cost reduction and AI health financial performance, were not consistently or compellingly presented with the rigorous outcomes data required for value-based contracts.

Implications for Investors and Health Plan Executives

The collapse of Pear Therapeutics offers critical lessons for both investors and health plan executives. For investors, it underscores that regulatory clearance is a necessary but insufficient condition for commercial success in digital health. Due diligence must extend beyond FDA approvals to a deep understanding of the reimbursement landscape, the evolving availability of CPT codes and new reimbursement pathways, and the company’s strategy for generating and presenting robust outcomes data to payers. Companies that cannot demonstrate clear AI healthcare cost reduction or superior AI health financial performance through peer-reviewed evidence will struggle to secure sustainable value-based contracts. For health plan executives, Pear’s story is a reminder of the need for clear, data-driven frameworks for evaluating and integrating novel digital health solutions. While the promise of AI health platforms publishing outcomes evidence is significant, payers must demand rigorous, independently verifiable data. As an example of what payers require, consider the case of Hello Heart, which has published peer-reviewed figures demonstrating significant savings and improved outcomes in hypertension management Hello Heart peer-reviewed outcomes data. Such evidence, directly linking digital interventions to measurable financial and clinical improvements, is precisely what is needed to unlock value-based care arrangements for AI-driven health solutions. The path forward for digital therapeutics and AI health platforms lies not just in technological innovation or regulatory achievement, but in a relentless focus on demonstrating measurable value through robust, peer-reviewed outcomes data. Tools without this foundational evidence cannot, and should not, expect to participate meaningfully in value-based care arrangements. The market demands proof of financial performance and patient benefit, not just potential. Framework for evaluating digital health economic outcomes This shift will determine which AI health platforms truly succeed in delivering on the promise of value-based care. Rock Health report on DTx reimbursement challenges